ABT

Abbott Laboratories
D

ABT

Arincen83/100B

Abbott Laboratories income statement 1985–2026

48.23B USD over the last twelve months, and 44.33B USD in fiscal year 2025.

Revenue Operating income Net income

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
30 Sept 2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
48.23B44.33B41.95B40.11B43.65B43.08B34.61B31.90B30.58B27.39B20.85B
Revenue growth
+10.00%+5.67%+4.59%-8.12%+1.34%+24.47%+8.48%+4.34%+11.64%+31.35%+2.20%
Cost of revenue
20.68B19.72B20.63B20.07B21.33B19.86B17.23B15.21B14.76B14.32B9.61B
Gross profit
27.55B24.61B21.33B20.04B22.32B23.21B17.38B16.69B15.82B13.07B11.24B
Gross margin
57.12%55.51%50.83%49.96%51.14%53.89%50.21%52.32%51.75%47.70%53.92%
Research and development
3.28B2.96B2.82B2.72B2.85B2.74B2.42B2.41B2.29B2.13B1.36B
Selling, general and administrative
14.57B12.38B11.65B10.88B11.11B11.28B9.67B9.69B9.69B8.96B6.64B
Operating expenses
20.20B16.59B14.47B13.60B13.96B14.01B12.09B12.10B11.98B11.09B8.00B
7.35B8.05B6.83B6.44B8.36B9.20B5.29B4.59B3.84B1.97B3.25B
Operating income growth
-5.60%+17.92%+6.06%-23.04%-9.11%+73.88%+15.25%+19.43%+94.93%-39.30%+10.17%
Operating margin
15.24%18.16%16.27%16.04%19.16%21.36%15.29%14.39%12.57%7.20%15.58%
Interest income
—230.00M344.00M385.00M183.00M43.00M46.00M94.00M105.00M124.00M99.00M
Interest expense
890.00M341.00M603.00M698.00M315.00M410.00M708.00M818.00M729.00M880.00M304.00M
Other non-operating income
-789.00M418.00M188.00M229.00M-56.00M-989.00M-323.00M-514.00M-971.00M259.00M-1.84B
Pretax income
6.56B8.47B7.01B6.66B8.31B8.21B4.97B4.08B2.87B2.23B1.41B
Income tax
1.86B1.94B-6.39B941.00M1.37B1.14B497.00M390.00M539.00M1.88B350.00M
Effective tax rate
28.36%22.94%-91.10%14.12%16.53%13.88%10.00%9.57%18.76%84.18%24.77%
4.70B6.52B13.40B5.72B6.93B7.07B4.50B3.69B2.37B477.00M1.40B
Net income growth
-66.37%-51.32%+134.18%-17.45%-1.95%+57.31%+21.91%+55.70%+396.44%-65.93%-68.35%
Net margin
9.75%14.72%31.95%14.27%15.88%16.42%12.99%11.56%7.74%1.74%6.71%
Basic shares
1.74B1.75B1.73B1.73B1.75B1.78B1.77B1.77B1.76B1.74B1.47B
1.74B1.75B1.75B1.75B1.76B1.79B1.79B1.78B1.77B1.75B1.48B
Change in diluted shares
-0.26%-0.06%-0.06%-0.85%-1.40%+0.17%+0.28%+0.62%+1.20%+17.94%-1.53%
EPS (basic)
2.703.747.673.303.943.972.522.071.350.270.95
2.703.727.643.273.913.942.502.061.340.270.94
EPS growth
-66.16%-51.31%+133.64%-16.37%-0.76%+57.60%+21.36%+53.73%+396.30%-71.28%-68.03%
Dividends per share
2.482.362.202.041.881.801.441.281.121.061.04
Dividend growth
+6.90%+7.27%+7.84%+8.51%+4.44%+25.00%+12.50%+14.29%+5.66%+1.92%+8.33%
EBITDA
9.71B11.92B10.83B10.61B11.89B12.16B9.00B7.91B6.88B6.13B3.07B
EBITDA margin
20.13%26.90%25.83%26.44%27.23%28.23%26.01%24.79%22.50%22.39%14.72%
EBIT
7.18B8.81B7.62B7.36B8.62B8.62B5.68B4.90B3.60B3.11B1.72B

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Common questions about Abbott Laboratories's income statement

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.